Japan

The move marks an important step toward evaluating the technology for Good Manufacturing Practice (GMP)-compliant manufacturing while improving the efficiency of producing next-generation medicines.

The Noguchi Institute’s newly licensed technology focuses on controlling two critical aspects of ADC design: the drug-to-antibody ratio (DAR) and the precise attachment site of the therapeutic payload.

Jascayd acts as the first phosphodiesterase 4B (PDE4B) inhibitor approved for these indications, offering both antifibrotic and immunomodulatory activity.

The treatment is approved in the United States for adults and pediatric patients aged six months and older, making it one of the few targeted therapies available for this condition.

The robot-assisted technologies under this agreement respond directly to this challenge by improving clinical outcomes and reducing procedural complications.

By integrating Aicuris into its global development and commercialization infrastructure, Asahi Kasei accelerates its expansion in the specialty pharmaceutical sector.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.

In Japan alone, 21,000 new cases and 7,000 deaths were reported that year, with metastatic renal cell carcinoma (RCC) accounting for approximately 85% of all kidney cancers.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.